Case 1:

The patient diagnosed with lung NUT carcinoma with clavicular and mediastinal lymph node metastasis in December 2022, the patient received 4 cycles of chemotherapy combined with immunotherapy (TP+Sintilimab) at an external hospital. In May 2023, targeted anti-tumor treatment with "NHWD-870" was initiated at our hospital.

2022-12: 9.1*5.2cm;

2023-05: 3.6*1.4cm;

2023-07: 3.0*1.4cm;

2023-10: 3.0*1.1cm;

2023-11: 2.9*1.0cm;

The patient underwent surgical resection in January 2024, and the pathological report after surgery showed no residual tumor tissue in the primary tumor site. Immunohistochemistry results were negative for NUT.

Case 2:

The patient diagnosed with lung NUT carcinoma with clavicular and mediastinal lymph node metastases in March 2023, the patient did not undergo anti-tumor treatment at the external hospital. In March 2023, the patient received "NHWD-870" targeted anti-tumor therapy at our hospital.

2023-03: 10.76*4.13cm;

2023-05: 7.25*2.32cm;

June 2023: Tumor size was 8.38*4.57cm; (progression with 870 monotherapy, TP added in July 2023)

2023-09: The lesion showed significant shrinkage compared to July, but the specific dimensions are not detailed;

The patient underwent surgical resection in November 2023, and the pathological report after surgery showed no residual tumor tissue. Immunohistochemistry: NUT (-).

The patient initially received monotherapy with "NHWD-870" targeted therapy for NUT carcinoma. However, due to inadequate disease control with monotherapy, TP chemotherapy was added, ultimately achieving complete remission.